15.10
Zymeworks Inc. stock is traded at $15.10, with a volume of 480.04K.
It is up +4.93% in the last 24 hours and up +5.45% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.39
Open:
$14.53
24h Volume:
480.04K
Relative Volume:
1.07
Market Cap:
$1.14B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-10.00
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
+5.15%
1M Performance:
+5.45%
6M Performance:
+4.93%
1Y Performance:
+35.30%
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ZYME
Zymeworks Inc.
|
15.10 | 1.06B | 62.71M | -112.51M | -96.01M | -1.51 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-20-25 | Initiated | TD Cowen | Buy |
Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Mar-21-23 | Resumed | Wells Fargo | Overweight |
Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Oct-04-22 | Resumed | Wells Fargo | Overweight |
May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
Mar-15-22 | Initiated | Evercore ISI | Outperform |
Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Nov-17-21 | Resumed | Guggenheim | Neutral |
Oct-07-21 | Initiated | Jefferies | Hold |
Mar-31-21 | Initiated | Credit Suisse | Outperform |
Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Feb-08-21 | Resumed | H.C. Wainwright | Buy |
Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
Sep-29-20 | Resumed | JP Morgan | Neutral |
Aug-06-20 | Initiated | SVB Leerink | Outperform |
Jan-10-20 | Initiated | Wolfe Research | Outperform |
Dec-09-19 | Initiated | JP Morgan | Neutral |
Nov-25-19 | Initiated | H.C. Wainwright | Buy |
Nov-20-19 | Initiated | Guggenheim | Buy |
Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Aug-30-19 | Initiated | Stifel | Buy |
Jul-18-19 | Initiated | Deutsche Bank | Buy |
May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Implied Analyst Target Price of $70.96 for iShares Morningstar Small-Cap ETF (ISCB) Suggests 16% Gain Potential. - AInvest
Zymeworks to Engage in Key Investor Conferences - TipRanks
Zymeworks to Participate in Upcoming Investor Conferences. - AInvest
Zymeworks' Strategic Momentum in 2025: A High-Conviction Biotech Play in the ADC and Bispecific Antibody Space - AInvest
Zymeworks Inc. to Participate in Multiple Upcoming Investor Conferences in September 2025 - Quiver Quantitative
Zymeworks to Present at Several Upcoming Investor Conferences - AInvest
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Biotech Zymeworks Lines Up 4 Major Wall Street Healthcare Conference Presentations in September - Stock Titan
RSI Crosses Above 30 for Zymeworks Inc. — Reversal in SightPortfolio Value Report & Weekly Watchlist of Top Performers - 선데이타임즈
Short Interest Drops in Zymeworks Inc. After RallyMarket Growth Review & Fast Moving Market Watchlists - newsimpact.co.kr
Is Zymeworks Inc. stock forming a triangle patternJuly 2025 Action & AI Forecast Swing Trade Picks - sundaytimes.kr
What is the cash position of Zymeworks Inc.2025 Winners & Losers & Weekly Momentum Stock Picks - mustnews.co.kr
Zymeworks Inc. Revenue Forecasts Upgraded by 44%: Analysts See Substantial Growth Ahead - AInvest
Growth Investors: Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 44% - Yahoo Finance
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - Caledon Enterprise
Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression - MSN
Will Breakout in Zymeworks Inc. Sustain Through Next WeekJuly 2025 Drop Watch & Free Technical Pattern Based Buy Signals - beatles.ru
Screener Results Flag Zymeworks Inc. as OversoldTrade Risk Assessment & Free Reliable Trade Execution Plans - thegnnews.com
Short Term Charts Align With Long Term Uptrend in Zymeworks Inc.July 2025 Review & Long-Term Capital Growth Strategies - sundaytimes.kr
Zymeworks Inc. Added to Custom Quant Screener Today2025 Buyback Activity & Free Fast Entry Momentum Trade Alerts - thegnnews.com
Zymeworks (ZYME) Is Up 12.3% After Board Shakeup, Insider Investment, and Return to Profitability – Has The Bull Case Changed? - simplywall.st
Zymeworks (NASDAQ:ZYME) Issues Earnings Results - MarketBeat
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Ariva
Zymeworks Strengthens Leadership with New Board Appointments - TipRanks
Zymeworks Expands Board with Financial Veterans Greg Ciongoli and Robert E. Landry - The Indian Awaaz
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry | ZYME Stock News - GuruFocus
Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors - Quiver Quantitative
Zymeworks appoints two new directors to strengthen board By Investing.com - Investing.com Canada
Zymeworks appoints two new directors to strengthen board - Investing.com India
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Will breakout in Zymeworks Inc. lead to full recoveryFree Breakout Entry Signal Confirmation Tool - Newser
Has Zymeworks Inc. formed a bullish divergenceLow Risk Stock Selection Strategy Guide - Newser
Zymeworks Inc. stock trendline breakdownFree Scalable Portfolio Growth Suggestions - Newser
Zymeworks Inc. stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - simplywall.st
Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Is Zymeworks Inc. forming a breakout patternDouble Capital Strategy Picks - thegnnews.com
Can Zymeworks Inc. hit a new high this monthFree Proven Entry Plan With Low Risk Trade - Newser
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Applying sector rotation models to Zymeworks Inc.Technical Reversal Setup with Risk Limits - Newser
What does recent volatility data suggest for Zymeworks Inc.Stock Price Prediction Using AI Tools - Newser
Why Zymeworks Inc. stock attracts strong analyst attentionFree High Yield Stocks With Buy Confirmation - Newser
Is Zymeworks Inc. affected by consumer sentimentStock Picks with 300% Gain - sisaissue.com
Zymeworks Q2 2025 Earnings Call: Capitalizing on Platform-Driven Innovation and Strategic Execution - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Purchases 4,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (NASDAQ:ZYME) Lowered to “Hold” Rating by Wall Street Zen - Defense World
Zymeworks Reports Strong Q2 2025 Financial Performance - The Globe and Mail
Zymeworks Reports Q2 Results and FDA Clearance - The Globe and Mail
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zymeworks Inc. Stock (ZYME) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
EcoR1 Capital, LLC | Director |
May 19 '25 |
Buy |
11.78 |
5,919 |
69,738 |
17,883,908 |
EcoR1 Capital, LLC | Director |
Apr 16 '25 |
Buy |
11.16 |
73,953 |
825,589 |
17,773,727 |
EcoR1 Capital, LLC | Director |
Apr 17 '25 |
Buy |
11.52 |
54,760 |
630,819 |
17,828,487 |
EcoR1 Capital, LLC | Director |
Apr 04 '25 |
Buy |
11.17 |
196,438 |
2,193,800 |
17,699,774 |
EcoR1 Capital, LLC | Director |
Apr 03 '25 |
Buy |
11.84 |
120,770 |
1,430,170 |
17,503,336 |
EcoR1 Capital, LLC | Director |
Apr 02 '25 |
Buy |
11.85 |
74,360 |
881,017 |
17,382,566 |
EcoR1 Capital, LLC | Director |
Apr 01 '25 |
Buy |
11.60 |
48,658 |
564,647 |
17,308,206 |
EcoR1 Capital, LLC | Director |
Mar 31 '25 |
Buy |
11.75 |
4,397 |
51,658 |
17,259,548 |
EcoR1 Capital, LLC | Director |
Mar 25 '25 |
Buy |
12.91 |
53,501 |
690,452 |
17,211,303 |
EcoR1 Capital, LLC | Director |
Mar 26 '25 |
Buy |
12.24 |
43,848 |
536,857 |
17,255,151 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):